Viruses as potential pathogenic agents in systemic lupus erythematosus

Lupus

Volumn 23, Issue 6, 2014, Pages 596-605

  Nelson, P ^a   Rylance, P ^b   Roden, D ^a   Trela, M ^a   Tugnet, N ^c  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

autoantibodies; autoimmunity; environmental factors; human endogenous retroviruses; molecular mimicry; peptides; Systemic lupus erythematosus

Indexed keywords

CROSS REACTING ANTIBODY; TOLL LIKE RECEPTOR;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; CAMPYLOBACTER ENTERITIS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS; DENGUE VIRUS; ENDOGENOUS RETROVIRUS; EPSTEIN BARR VIRUS; GROUP A STREPTOCOCCAL INFECTION; GUILLAIN BARRE SYNDROME; HERPES SIMPLEX VIRUS; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 7; HUMAN PARVOVIRUS B19; IMMUNE DYSREGULATION; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; META ANALYSIS; MOLECULAR MIMICRY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TORQUE TENO VIRUS; VIRUS VIRULENCE; WART VIRUS; ANIMAL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOGENICITY; RISK ASSESSMENT; RISK FACTOR; VIROLOGY; VIRUS; VIRUS DISEASES;

ANIMALS; AUTOIMMUNITY; HOST-PATHOGEN INTERACTIONS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR MIMICRY; RISK ASSESSMENT; RISK FACTORS; VIRUS DISEASES; VIRUSES;

EID: 84899506816     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314531637     Document Type: Article

References (107)

1. Bertsias G, Cervera R, Boumpas DT EULAR textbook on rheumatic diseases. Bijlsma J, ed. London: BMJ Group ; 2012: 476-505.
2. Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A. Environment and systemic lupus erythematosus: an overview. Autoimmunity. 2005 ; 38: 465-472
3. Diem O, Schaffner M, Seifarth W, Leib-Mosch C. Influence of antipsychotic drugs on human endogenous retroviruses (HERV) transcription in brain cells. PLos ONE. 2012 ; 7: 1-8
4. Shoenfeld N, Amital H, Shoenfeld Y. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol. 2009 ; 5: 99-1052
5. Birmingham DJ, Hebert LA, Song H, et al. Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus. 2012 ; 21: 855-864
6. Javierre BM, Hernando H, Ballestar E. Environmental triggers and epigenetic deregulation in autoimmune disease. Discov Med. 2011 ; 12: 535-545
7. Dedeoglu F. Drug-induced autoimmunity. Curr Opin Rheumatol. 2009 ; 21: 547-551
8. Tugnett N, Rylance P, Roden D, Trela M, Nelson P. Human endogenous retroviruses (HERVs) and autoimmune rheumatic disease: is there a link?. Open Rheumatol J. 2013 ; 7: 13-21
9. Riemekasten G, Hahn BH. Key autoantigens in SLE. Rheumatology. 2005 ; 44: 975-982
10. Silverman GJ, Srikrishnan R, Germar K, et al. Genetic imprinting of autoantibody repertoires in systemic lupus erythematosus patients. Clin Exp Immunol. 2008 ; 153: 102-116
11. Dale JB, Beachey EH. Epitopes of streptococcal M proteins shared with cardiac myosin. J Exp Med. 1985 ; 162: 583-591
12. Faé KC, da Silva DD, Oshiro SE, et al. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol. 2006 ; 176: 5662-5670
13. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology. 1990 ; 40: 1900-1902
14. Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med. 2008 ; 14: 1088-1096
15. Francis L, Perl A. Infection in systemic lupus erythematosus: friend or foe?. Int J Clin Rheumatol. 2010 ; 5: 59-74
16. James JA, Robertson JM. Lupus and Epstein-Barr. Curr Opin Rheumatol. 2012 ; 24: 383-388
17. Mohamed AE, Hasen AM, Mohammed GF, Elmaraghy NN. Real-time PCR of cytomegalovirus and Epstein-Barr virus in adult Egyptian patients with systemic lupus erythematosus. Int J Rheum Dis. Epub ahead of print 16 December 2013. DOI: 10.1111/1756-185X.12261.
18. Pavlovic M, Kats A, Cavallo M, Shoenfeld Y. Clinical and molecular evidence for association of SLE with parvovirus B19. Lupus. 2010 ; 19: 783-792
19. Rigante D, Mazzoni MB, Esposito S. The cryptic interplay between systemic lupus erythematosus and infections. Autoimmun Rev. 2013 ; 13: 96-102
20. Broccolo F, Drago F, Cassina G. Selective reactivation of human herpesvirus 6 in patients with autoimmune connective tissue diseases. J Med Virol. 2013 ; 85: 1925-1934
21. Tung YC, Ke LY, Tsai SM, Lu PL, Tsai WC. High seroprevalence of human herpesvirus 8 infection in patients with systemic lupus erythematosus. Int J Rheum Dis. 2013 ; 16: 709-714
22. Talib S, Bhattu S, Bhattu R, Deshpande S, Dahiphale D. Dengue fever triggering systemic lupus erythematosus and lupus nephritis: a case report. Int Med Case Rep J. 2013 ; 6: 71-75
23. Chang D, Tsai RT, Wang M, Ou WC. Different genotypes of human polyomaviruses found in patients with autoimmune diseases in Taiwan. J Med Virol. 1996 ; 48: 204-209
24. Abud-Mendoza C, Cuevas-Orta E, Santillán-Guerrero EN, et al. Decreased blood levels of B lymphocytes and NK cells in patients with systemic lupus erythematosus (SLE) infected with papillomavirus (HPV). Arch Dermatol Res. 2013 ; 305: 117-123
25. Shirdel A, Hashemzadeh K, Sahebari M, et al. Is there any association between human lymphotropic virus type I (HTLV-I) infection and systemic lupus erythematosus? An original research and literature review. Iran J Basic Med Sci. 2013 ; 16: 252-257
26. Carugati M, Franzetti M, Torre A, et al. Systemic lupus erythematosus and HIV infection: a whimsical relationship. Reports of two cases and review of the literature. Clin Rheumatol. 2013 ; 32: 1399-1405
27. Flavell KJ, Biddulph JP, Lowe D, et al. Effect of material deprivation on the frequency of Epstein-Barr virus infection in childhood Hodgkin's disease. Br J Cancer. 2001 ; 85: 350-356
28. Mikhalkova D, Khanna S, Vaidya R, Sethi S, Hogan MC. Epstein-Barr virus associated nephrotic syndrome. Clin Kidney J. 2012 ; 5: 50-52
29. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997 ; 100: 3019-3026
30. Poole BD, Templeton AK, Guthridge JM, Brown EJ, Harley JB, James JA. Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev. 2009 ; 8: 337-342
31. Kitagawa H, Iho S, Yokochi T, Hoshino T. Detection of antibodies to the Epstein-Barr virus nuclear antigens in the sera from patients with systemic lupus erythematosus. Immunol Lett. 1988 ; 17: 249-252
32. Kang I, Quan T, Nolasco H, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol. 2004 ; 172: 1287-1294
33. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. J Immunol. 2005 ; 174: 6599-6607
34. Hanlon P, Avenell A, Aucott L, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther. Epub ahead of print 6 January 2014. DOI: 10.1186/ar4429.
35. Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol. 2008 ; 22: 883-896
36. Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity. 2001 ; 15: 579-589
37. Torres BA, Kominsky S, Perrin GQ, Hobeika AC, Johnson HM. Superantigens: the good, the bad, and the ugly. Exp Biol Med. 2001 ; 226: 164-176
38. Nelson PN, Freimanis G, Roden D. Human endogenous retroviruses; evolutionary dynamics, chromosomal location and host benefit. In: Encyclopedia of life sciences. Hoboken, NJ, USA: John Wiley & Sons, 2008, pp. 1-6.
39. Hohn O, Hanke K, Bannert N. HERV-K(HML-2), the best preserved family of HERVs: endogenization, expression, and implications in health and disease. Front Oncol. 2013 ; 3: 1-12
40. Tristem M. Identification and characterization of novel human endogenous retrovirus families by phylogenetic screening of the human genome mapping project database. J Virol. 2000 ; 74: 3715-3730
41. Nelson PN, Carnegie PR, Martin J, et al. Demystified. human endogenous retroviruses. Mol Pathol. 2003 ; 56: 11-18
42. Winter EE, Goodstadt L, Ponting GP. Elevated rates of protein secretion, evolution, and disease among tissue-specific genes. Genome Res. 2004 ; 14: 54-61
43. Lower R, Lower J, Kurth R. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci USA. 1996 ; 93: 5177-5184
44. Nelson PN, Hooley P, Roden D, et al. Human endogenous retroviruses: transposable elements with potential?. Clin Exp Immunol. 2004 ; 138: 1-9
45. Moyes D, Griffiths DJ, Venables PJ. Insertional polymorphisms: a new lease of life for endogenous retroviruses in human disease. Trends Genet. 2007 ; 23: 326-333
46. Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus. 2009 ; 18: 1136-1143
47. Talal N, Garry RF, Schur PH, et al. A conserved idiotype and antibodies to retroviral proteins in systemic lupus erythematosus. J Clin Invest. 1990 ; 85: 1866-1871
48. Nelson PN. Retroviruses in rheumatic diseases. Ann Rheum Dis. 1995 ; 55: 441-442
49. Nelson PN, Lever AML, Bruckner FE, Isenberg DA, Kessaris N, Hay FC. Polymerase chain reaction fails to incriminate exogenous retroviruses HTLV-I and HIV-1 in rheumatological diseases although a minority of sera cross-react with retroviral antigens. Ann Rheum Dis. 1994 ; 53: 749-754
50. Martin MA, Bryan T, Rasheed S, Khan AS. Identification and cloning of endogenous retroviral sequences present in human DNA. Proc Natl Acad Sci USA. 1981 ; 78: 4892-4896
51. Perl A. Role of endogenous retroviruses in autoimmune diseases. Rheum Dis Clin N Am. 2003 ; 29: 123-143
52. Balada E, Ordi-Ros J, Vilardell-Tarres M. Molecular mechanisms mediated by human endogenous retroviruses (HERVs) in autoimmunity. Rev Med Virol. 2009 ; 19: 273-286
53. Perl A, Rosenblatt JD, Chen ISY, et al. Detection and cloning of new HTLV-related endogenous sequences in man. Nucleic Acids Res. 1989 ; 1: 6841-6854
54. Tsao BP, Cantor RM, Kalunian KC, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest. 1997 ; 99: 725-731
55. Pullmann RJ, Bonilla E, Phillips PE, Middleton FA, Perl A. Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum. 2008 ; 58: 532-540
56. Magistrelli C, Samoilova E, Agarwal RK, et al. Polymorphic genotypes of the HRES-1 human endogenous retrovirus locus correlate with systemic lupus erythematosus and autoreactivity. Immunogenetics. 1999 ; 49: 829-834
57. Perl A, Fernandez D, Telarico T, Phillips PE. Endogenous retroviral pathogenesis in lupus. Curr Opin Rheumatol. 2010 ; 22: 483-492
58. Banki K, Maceda J, Hurley E, et al. Human T-cell lymphotropic virus (HTLV)-related endogenous sequence, HRES-1, encodes a 28-kDa protein: a possible autoantigen for HTLV-I gag-reactive autoantibodies. Proc Natl Acad Sci USA. 1992 ; 89: 1939-1943
59. Brookes SM, Pandolfino YA, Mitchell TJ, et al. The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br J Rheumatol. 1992 ; 31: 735-742
60. Perl A, Colombo E, Dai H, et al. Antibody reactivity to the hres-1 endogenous retroviral element identifies a subset of patients with systemic lupus erythematosus and overlap syndromes. Correlation with antinuclear antibodies and HLA class II alleles. Arthritis Rheum. 1995 ; 38: 1660-1671
61. Rylance P, Nelson P, Trela M, Roden D, Subramanian S, Tugnet N. Bioinformatic analysis of human endogenous retrovirus HRES-1 indicates a potential viral trigger for systemic lupus erythematosus (SLE), http://www.renalarchive.org/FetchDoc.aspx?id=7634 (2013, accessed 10 March 2014).
62. Nagy G, Ward J, Mosser DD, et al. Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. J Biol Chem. 2006 ; 281: 34574-34591
63. Perl A, Fernandez D, Telarico T, Phillips PE. Endogenous retroviral pathogenesis in lupus. Curr Opin Rheumatol. 2010 ; 22: 483-492
64. O'Connell C, O'Brien S, Nash WG, Cohen M. ERV3, a full-length human endogenous provirus: chromosomal localization and evolutionary relationships. Virology. 1984 ; 138: 225-235
65. Leib-Mosch C, Brack-Werner R, Werner T, et al. Endogenous retroviral elements in human DNA. Cancer Res. 1990 ; 50: 5636S - 5642S
66. De Parseval N, Heidmann T. Physiological knockout of the envelope gene of the single-copy ERV-3 human endogenous retrovirus in a fraction of the Caucasian population. J Virol. 1998 ; 72: 3442-3445
67. Li JM, Fan W, Horsfall AC, et al. The expression of human endogenous retrovirus-3 in fetal cardiac tissue and antibodies in congenital heart block. Clin Exp Immunol. 1996 ; 104: 388-393
68. Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus. 2009 ; 18: 1136-1143
69. Nelson PN, Davari Ejtehadi H, Nevill A, Bowman S. Endogenous retrovirus ERV-3 is not implicated in rheumatoid arthritis but may provide a biomarker for osteoarthritis. J Rheumatol. 2010 ; 37: 473-473
70. Ogasawara H, Hishikawa T, Sekigawa I, Hashimoto H, Yamamoto N, Maruyama N. Sequence analysis of human endogenous retrovirus clone 4-1 in systemic lupus erythematosus. Autoimmunity. 2001 ; 33: 15-21
71. Repaske R, Steele PE, O'Neill RR, Rabson AB, Martin MA. Nucleotide sequence of a full-length human endogenous retroviral segment. J Virol. 1985 ; 54: 764-772
72. Ogasawara H, Naito T, Kaneko H, Hishikawa T, Sekigawa I, Hashimoto K, et al. Quantitative analyses of messenger RNA of human endogenous retrovirus in patients with systemic lupus erythematosus. J Rheumatol. 2001 ; 28: 533-538
73. Piotrowski PC, Duriagin S, Jagodzinski PP. Expression of human endogenous retrovirus clone 4-1 may correlate with blood plasma concentration of anti-U1 RNP and anti-Sm nuclear antibodies. Clin Rheumatol. 2005 ; 24: 620-624
74. Hishikawa T, Ogasawara H, Kaneko H, et al. Detection of antibodies to a recombinant gag protein derived from human endogenous retrovirus clone 4-1 in autoimmune diseases. Viral immunology. 1997 ; 10: 137-147
75. Naito T, Ogasawara H, Kaneko H, et al. Immune abnormalities induced by human endogenous retroviral peptides: with reference to the pathogenesis of systemic lupus erythematosus. J Clin Immunol. 2003 ; 23: 371-376
76. Nelson P, Trela M, Roden D et al. Rheumatoid arthritis is associated with IgG antibodies to human endogenous retrovirus HERV-K10 gag matrix; a potential pathogenic mechanism of disease? Paper submitted for publication, J Rheumatol 2014.
77. Ono M. Molecular cloning and long terminal repeat sequences of human endogenous retrovirus genes related to types A and B retrovirus genes. J Virol. 1986 ; 58: 937-944
78. Nelson NP, Shaw M, Roden D, Freimanis GL, Nevill AM, Rylance P. Human endogenous retrovirus HERV-K10 implicated in rheumatoid arthritis and systemic lupus erythematosus: potential pathological triggers?. Biomed Papers. 2006 ; 150: 29S - 30S
79. Herve CA, Lugli EB, Brand A, Griffiths DJ, Venables PJ. Autoantibodies to human endogenous retrovirus-K are frequently detected in health and disease and react with multiple epitopes. Clin Exp Immunol. 2002 ; 128: 75-82
80. Nelson PN, Lever AM, Smith S, et al. Molecular investigations implicate human endogenous retroviruses as mediators of anti-retroviral antibodies in autoimmune rheumatic disease. Immunol Invest. 1999 ; 28: 277-289
81. Freimanis G, Hooley P, Ejtehadi HD, et al. A role for human endogenous retrovirus-K (HML-2) in rheumatoid arthritis: investigating mechanisms of pathogenesis. Clin Exp Immunol. 2010 ; 160: 340-347
82. Perl A. Mechanisms of viral pathogenesis in rheumatic disease. Ann Rheum Dis. 1999 ; 58: 454-461
83. Garry RF, Fermin CD, Hart DJ, Alexander SS, Donehower LA, Luo-Zhang H. Detection of a human intracisternal A-type retroviral particle antigenically related to HIV. Science. 1990 ; 250: 1127-1129
84. Sander DM, Szabo S, Gallaher WR, et al. Involvement of human intracisternal A-type retroviral particles in autoimmunity. Microsc Res Tech. 2005 ; 68: 222-234
85. Deas JE, Thompson JJ, Fermin CD, et al. Viral induction, transmission and apoptosis among cells infected by a human intracisternal A-type retrovirus. Virus Res. 1999 ; 61: 19-27
86. Roden D, Ejtehadi H, Rowland-Jones S, et al. Use of bioinformatics to highlight antigenic regions of exogenous and endogenous retroviruses. Immunology. 2001 ; 104: S112-113
87. Westwood Nelson PN, Westwood OMR, Freimains G, Roden D, Rylance PB, Sassouri S, et al. Antigenic regions on IgG1Fc identified using bioinformatics and monoclonal rheumatoid factors: a preliminary study. Clinical Med Arthritis Musculoskeletal Dis. 2008 ; 1: 1-10
88. Nelson PN Epitope mapping: a practical approach. Westwood OMR FC Hay FC, ed. Oxford, UK: Oxford University Press ; 2001: 159-197.
89. Nelson PN, Westwood OMR, Soltys A, et al. Characterisation of epitopes of pan-IgG/anti-G3m(u) and anti-Fc monoclonal antibodies. Imm Lett. 2003 ; 88: 77-83
90. Tudos E, Cserzo M, Simon I. Predicting isomorphic residue replacements for protein design. Int J Pept Protein Res. 1990 ; 36: 236-239
91. Davari Ejtehadi H, Martin JH, Jung J, et al. A novel multiplex RT-PCR system detects human endogenous retrovirus-K in breast cancer. Arch Virol. 2005 ; 150: 177-184
92. Ono M, Kawakami M, Ushikubo H. Stimulation of expression of the human endogenous retrovirus genome by female steroid hormones in human breast cancer cell line T47D. J Virol. 1987 ; 61: 2059-2062
93. Sibata M, Ikeda H, Katumata K, Takeuchi K, Wakisaka A, Yoshoki T. Human endogenous retroviruses: expression in various organs in vivo and its regulation in vitro. Leukemia. 1997 ; 11: 145-146
94. Okada M, Ogasawara H, Kaneko H, et al. Role of DNA methylation in transcription of human endogenous retrovirus in the pathogenesis of systemic lupus erythematosus. J Rheumatol. 2002 ; 29: 1678-1682
95. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature. 1998 ; 395: 89-93
96. Javierre BM, Fernandez AF, Richter J, et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010 ; 20: 170-179
97. Mizugaki M, Yamaguchi T, Ishiwata S, et al. Alteration of DNA methylation levels in MRL lupus mice. Clin Exp Immunol. 1997 ; 110: 265-269
98. Balada E, Ordi-Ros J, Vilardell-Tarres M. DNA methylation and systemic lupus erythematosus. Ann N Y Acad Sci. 2007 ; 1108: 127-136
99. Zhou Y, Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun Rev. 2008 ; 7: 376-383
100. Okada M, Ogasawara H, Kaneko H, et al. Role of DNA methylation in transcription of human endogenous retrovirus in the pathogenesis of systemic lupus erythematosus. J Rheumatol. 2002 ; 29: 1678-1682
101. Balada E, Vilardell-Tarrès M, Ordi-Ros J. Implication of human endogenous retroviruses in the development of autoimmune diseases. Int Rev Immunol. 2010 ; 29: 351-370
102. Hohenadl C, Germaier H, Walchner M, et al. Transcriptional activation of endogenous retroviral sequences in human epidermal keratinocytes by UVB irradiation. J Invest Dermatol. 1999 ; 113: 587-594
103. Emlen W, Niebur JA, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994 ; 152: 3685-3692
104. Mudd PA, Teague BN, Farris AD. Regulatory T cells and systemic lupus erythematosus. Scand J Immunol. 2006 ; 64: 211-218
105. Ellerhorst JA, Cooksley CD, Grimm EA. Autoimmunity and hypothyroidism in patients with uveal melanoma. Melanoma Res. 2001 ; 11: 633-637
106. Von Herrath MG, Boon B, Lewicki H, Mazarguil H, Gairin JE, Oldstone MBA. In vivo treatment with a MHC Class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes. J Immunol. 1998 ; 161: 5087-5096
107. Fridkis-Hareli M. Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders. Clin Dev Immunol. Epub ahead of print 13 November 2013. DOI: 10.1155/2013/826191.